Form 4: Vaxcyte Director Acquires Shares and Options

Vaxcyte Director John Furey reported the acquisition of 2,265 shares of common stock and 11,389 stock options on June 15, 2026.

Summary

• Director John Furey acquired 2,265 shares of Vaxcyte, Inc. common stock on June 15, 2026, with no cost reported for this transaction.
• Following this acquisition, Furey beneficially owns 5,306 shares of common stock.
• Additionally, Furey acquired a stock option to purchase 11,389 shares of common stock at an exercise price of $49.56, with an expiration date of June 15, 2036.
• These options are subject to vesting conditions, with full vesting expected by June 15, 2027, or the day prior to the next annual meeting, contingent on continuous service.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as director stock acquisitions can signal confidence, but the details of the options require significant future stock appreciation to become valuable.

Positives

• Director acquisition of company stock can signal confidence in the company's future prospects.
• The acquisition of stock options indicates a long-term incentive aligned with potential share price appreciation.

Risks

• The vesting schedule for RSUs and stock options means that the full benefit of these awards is contingent on continued employment.
• The exercise price of the stock option ($49.56) is significantly higher than the current market price, implying a substantial increase in share price is needed for the options to be profitable.

Future Outlook

The vesting of RSUs and stock options is tied to continued service and specific future dates, indicating management's long-term commitment and alignment with future company performance.

Industry Context

StockSavvy.ai notes that insider transactions, such as this Form 4 filing by a Vaxcyte director, are closely watched by the market as potential indicators of management's confidence in the company's valuation and future prospects within the biotechnology sector.

Stakeholder Impact

• Shareholders: The acquisition of stock by a director may be interpreted as a positive signal of confidence, potentially influencing investor sentiment.
• Employees: The vesting conditions for RSUs and options highlight the importance of continued employment for key personnel to realize their compensation.
• Management: The stock option grant aligns management's financial interests with the long-term success and stock price appreciation of Vaxcyte.

Next Steps

• Continuous service by John Furey through the vesting dates to realize the full benefit of RSUs and stock options.
• Monitoring of Vaxcyte's stock performance relative to the $49.56 option exercise price.

Key Dates

Keywords

Vaxcyte, PCVX, Form 4, Insider Trading, Stock Options, Restricted Stock Units, Director, Beneficial Ownership, Securities Exchange Act